Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.

Blood - 10 Apr 2014

Hähnel Patricia S, Enders Birgit, Sasca Daniel, Roos Wynand P, Kaina Bernd, Bullinger Lars, Theobald Matthias, Kindler Thomas

Abstract excerpt

Activating KRAS mutations are detected in a substantial number of hematologic malignancies. In a murine T-cell acute lymphoblastic leukemia (T-ALL) model, we previously showed that expression of oncogenic Kras induced a premalignant state accompanied with an arrest in T-cell differentiation and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Comet Assay
Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Breaks, Double-Stranded

Share to DNA Repair

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Proto-Oncogene Proteins p21(ras)

Share to Transduction, Genetic

Source

Identifiers

PMID: 24505083
DOI: 10.1182/blood-2013-01-477620

Genes

KRAS
PARP1
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24505083-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.PMID 24505083Read ↗

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ HeelSemantic proximity Read ↗

Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapiesSemantic proximity Read ↗

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectivesSemantic proximity Read ↗

A novel KU70-mutant human leukemic cell line generated using CRISPR-Cas9 shows increased sensitivity to DSB inducing agents and reduced NHEJ activitySemantic proximity Read ↗

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.Semantic proximity Read ↗

Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the StageSemantic proximity Read ↗

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Semantic proximity Read ↗

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated LeukemiasSemantic proximity Read ↗

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.Semantic proximity Read ↗

The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.Semantic proximity Read ↗

The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and CancerSemantic proximity Read ↗

Loss of function of <i>Atrx</i> leads to activation of alternative lengthening of telomeres in a primary mouse model of sarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.